Fig. 1

Study design. a Trend analysis. b Treatment patterns, patient characteristics and AE analysis. The study periods are indicated as durations between closed circles. The index date (date of 1 L treatment initiation for mRCC) could occur during the index period. Patients were followed up for a minimum of 6 months until the end of continuous enrollment. The end of 1 L treatment was defined as the last 1 L treatment claim date plus (1) the number of days of supply of the oral treatments (last claim) or (2) the labeled cycle length for the IV treatments. Time to 2 L treatment (TT2T) was defined as the initiation of a new 1 L therapy regimen > 30 days following the index date or restart of 1 L index treatment following a > 3-month gap